Vertex Inc. (VERX)
Final Trades: Vertex Pharma, Netflix and the IYF
The Investment Committee give you their stop stocks to watch for the second half.
Vertex: Expectations Reset With Improved Fundamentals (Rating Upgrade)
I upgrade my rating for Vertex stock to buy due to the recent valuation pullback, creating an attractive entry point at 7x forward revenue. VERX's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24 and management projecting 28% y/y growth for FY25. ERP migrations from SAP and Oracle provide a multiyear pipeline, with a $1.8 billion TAM through 2028, supporting ARR growth.
Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals
Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBC's “Halftime Report” to explain why he's buying the Pharmaceutical company
As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy Point
Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock is among top biotechs to watch.
Goldman Sachs Analyst Anticipates Clarity On Vertex's Investment Roadmap And Product Monetization At Investor Day
Goldman Sachs analyst Adam Hotchkiss expressed expectations on Vertex, Inc. VERX ahead of its first Investor Day as a public company on March 19.
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?
Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress.
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals. The company's 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification efforts include the approval of pain therapy JOURNAVX and gene therapy Casgevy, with potential multi-billion-dollar revenue contributions from these and other pipeline drugs.
Trade Tracker: Rob Sechan sells McDonald's and Vertex, buys Texas Pacific Land, Amgen and NRG
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves.
Vertex, Inc. (VERX) Q4 2024 Earnings Call Transcript
Vertex, Inc. (NASDAQ:VERX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Joe Crivelli – Vice President of Investor Relations David DeStefano – President and Chief Executive Officer John Schwab – Chief Financial Officer Conference Call Participants Rob Oliver – Baird Chris Quintero – Morgan Stanley Joshua Reilly – Needham Samad Samana – Jefferies Steve Enders – Citi Daniel Jester – BMO Capital Markets Jacob Roberge – William Blair Alex Sklar – Raymond James Patrick Walravens – Citizens William Jellison – D.A. Davidson Adam Hotchkiss – Goldman Sachs Operator Good morning and welcome to the Vertex Incorporated Fourth Quarter 2024 Earnings Conference Call.
Here's What Key Metrics Tell Us About Vertex (VERX) Q4 Earnings
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Vertex (VERX) Tops Q4 Earnings and Revenue Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago.
Vertex to Report Q4 Earnings: What's in Store for the Stock?
VERX's fourth-quarter 2024 performance is likely to have benefited from the growing adoption of cloud-based tax automation solutions.
